Lilly/Incyte's baricitinib still has more to do in RA
This article was originally published in Scrip
The full data for Lilly/Incyte's Phase III RA-BUILD and RA-BEACON studies of their novel oral JAK 1 and 2 inhibitor baricitinib presented at EULAR in Rome this week confirm its promising efficacy but some experts want to see still more safety data.
You may also be interested in...
Lilly priced its now-approved Olumiant (baricitinib) to fight for US market share versus well-known rheumatoid arthritis therapies, undercutting Humira by 60% and Pfizer's established JAK inhibitor Xeljanz by 50%.
The Russian ministry of health has raised eyebrows by approving a vaccine against SARS-CoV-2 just weeks after its first clinical trials in 76 volunteers. Phase III confirmatory studies await for the adenovirus-based product but a mass vaccination plan is slated to begin in October.
A first look at the clinical data for Novavax’s COVID-19 vaccine suggests it can produce strong antibody responses while being well tolerated.